Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
University of Washington
Samsung Medical Center
Stanford University
Seagen Inc.
Seagen Inc.
Seagen Inc.
National Cancer Institute (NCI)